Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study ; volume:44 ; number:7 ; day:27 ; month:6 ; year:2024 ; pages:513-525 ; date:7.2024
Clinical drug investigation ; 44, Heft 7 (27.6.2024), 513-525, 7.2024

Creator
Mohan, M. V. T. Krishna
Prajapati, Arpitkumar
Kothari, Rushabh
Mandal, Srikrishna
Srikanth, Ranganatha Rao
Nagarkar, Rajnish
Khane, Shriram
Santa, Ayyagari
Dadke, Disha
Contributor
SpringerLink (Online service)

DOI
10.1007/s40261-024-01374-y
URN
urn:nbn:de:101:1-2410072116278.986556104899
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Mohan, M. V. T. Krishna
  • Prajapati, Arpitkumar
  • Kothari, Rushabh
  • Mandal, Srikrishna
  • Srikanth, Ranganatha Rao
  • Nagarkar, Rajnish
  • Khane, Shriram
  • Santa, Ayyagari
  • Dadke, Disha
  • SpringerLink (Online service)

Other Objects (12)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018

Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population

Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

How We Treat HER2-Positive Metastatic Breast Cancer

How We Treat HER2-Positive Metastatic Breast Cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Related objects